{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"Prospektive, multizentrische Registerstudie zur Bewertung verschiedener leitlinienkonformer Operationsverfahren in der Axilla (Sentinel-Node Biopsie, Targeted Axillary Dissection, Axilladissektion) nach neoadjuvanter Chemotherapie","eudractNumber":null,"id":7644,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04373655","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2020-06-04T10:22:01+02:00","shortTitle":"AXSANA / EUBREAST 3 – Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations (AndroMETa-Lung-536)","eudractNumber":"2024-514465-18","id":10833,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06772623","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2026-05-06T13:19:45+02:00","shortTitle":"AbbVie M24-536 [AndroMETa-Lung-536]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 2/3 Open Label Randomized Study of\nTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally\nAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer\nAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713","eudractNumber":"2025-521124-29-00","id":11332,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT07155187","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2026-03-02T10:56:01+01:00","shortTitle":"Abbvie M25-713 AndroMETa-Lung-713","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Adjuvante Therapie mit Mitotane vs. Mitotane mit Cisplatin und Etoposid nach primärer Resektion eines \nlokalisierten Nebennierenrindenkarzinoms mit hohem Rezidivrisiko (ADIUVO-2-Studie) - eine pragmatische, \nrandomisierte, minimalinterventionelle Phase III Studie mit Beobachtungsarm","eudractNumber":"2022-500013-32-01","id":10842,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03583710","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-27T12:21:02+01:00","shortTitle":"Adiuvo-2 / AIO-ENC-0123/ass","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Allogene Stammzelltransplantation im Vergleich zur konventionellen \nTherapie als Salvage-Therapie für Patienten mit rezidiviertem / \nprogredientem multiplen Myelom nach einer Erstlinientherapie\n(AlloRelapseMMStudy)","eudractNumber":"2021-001005-67","id":8119,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05675319","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-04-05T10:24:45+02:00","shortTitle":"AlloRelapseMMStudy - CTC201637","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients","eudractNumber":"2025-523990-40-00","id":12095,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-07-07T08:46:17+02:00","shortTitle":"AugMMent/DSMM XXI","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Encorafenib Plus Binimetinib in Patients With Locally Advanced, \nUnresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, \nMultinational, Prospective, Longitudinal, Non-interventional Study in \nGermany, Austria and Switzerland","eudractNumber":null,"id":5940,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT04045691","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2019-10-31T08:21:58+01:00","shortTitle":"BERING MELANOMA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/ Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma and t(11; 14)","eudractNumber":"2021-003614-39","id":9079,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT04973605","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2025-05-07T12:24:50+02:00","shortTitle":"BGB-11417-105","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Big Heart Registry","eudractNumber":null,"id":8589,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-06-15T09:21:01+02:00","shortTitle":"BHR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"DAREON®-Lung-1: A Phase III multi-center,\nopen-label, randomised trial of intravenous obrixtamig in combination with\natezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and\netoposide as first-line treatment in patients with extensive-stage small cell\nlung cancer","eudractNumber":"2025-520565-51-00","id":11554,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-07-28T12:21:28+02:00","shortTitle":"BI - 1438-0012 DAREON Lung 1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]}]}